Earnings Releases·Nov 5, 2026, 7:05 AM ET

Zoetis — Third Quarter 2026 Earnings Summary

Reported revenue decreased 1% to $2.4 billion, while net income and diluted EPS fell 18% and 12% respectively to $591 million and $1.44 due to $133 million in significant pre-tax charges, including $89 million in asset impairments.
Full-year 2026 adjusted net income and EPS guidance were raised to $2.600–$2.640 billion and $6.25–$6.35, though revenue guidance was narrowed to $9.220–$9.320 billion reflecting (2)% to (1)% organic operational growth.
U.S. Companion Animal revenue declined 8% amid price sensitivity and generic competition, while International Livestock grew 9% organically driven by cattle and fish segments.
Strategic pipeline progress includes FDA approval for Convenia® RTU expected Q1 2027, EUA for Simparica Trio for screwworms, and accelerated timing for select 2027 product approvals to Q4 2026.